Physician Awareness and Utilization of Food and Drug Administration (FDA)-Approved Labeling for Pharmacogenomic Testing Information
Open Access
- 10 June 2013
- journal article
- research article
- Published by MDPI AG in Journal of Personalized Medicine
- Vol. 3 (2) , 111-123
Abstract
We surveyed 10,303 United States physicians on where they obtain pharmacogenomic testing information. Thirty-nine percent indicated that they obtained this from drug labeling. Factors positively associated with this response included older age, postgraduate instruction, using other information sources, regulatory approval/ recommendation of testing, reliance on labeling for information, and perception that patients have benefited from testing. Physicians use pharmacogenomic testing information from drug labeling, highlighting the importance of labeling information that is conducive to practice application.Keywords
This publication has 6 references indexed in Scilit:
- Adoption of Pharmacogenomic Testing by US Physicians: Results of a Nationwide SurveyClinical Pharmacology & Therapeutics, 2012
- Personalised medicine in Canada: a survey of adoption and practice in oncology, cardiology and family medicineBMJ Open, 2011
- Knowledge and Attitudes Concerning Pharmacogenomics Among Healthcare ProfessionalsPersonalized Medicine, 2011
- Abacavir hypersensitivity: a model system for pharmacogenetic test adoptionGenetics in Medicine, 2008
- Pharmacogenomic Biomarker Information in Drug Labels Approved by the United States Food and Drug Administration: Prevalence of Related Drug UsePharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2008
- Availability of pharmacogenomics-based prescribing information in drug package inserts for currently approved drugsThe Pharmacogenomics Journal, 2004